<DOC>
	<DOCNO>NCT02841137</DOCNO>
	<brief_summary>This phase II study intend determine effect progesterone 5 , 10 20 mg tablet compare progesterone 100 mg capsule endometrial thickness post-menopausal woman hormone therapy estradiol .</brief_summary>
	<brief_title>Efficacy Study Progesterone Tablet Post-menopausal Women</brief_title>
	<detailed_description />
	<mesh_term>Progesterone</mesh_term>
	<criteria>1 . Availability entire study period 2 . Postmenopausal female define : least 12 consecutive month spontaneous amenorrhea less 10 year spontaneous amenorrhea , Folliclestimulating hormone ( FSH ) level &gt; 40 milli International Units/ml 3 . Females intact uterus 4 . Moderate severe climacteric vasomotor symptoms 5 . Aged least 40 year old 65 year 6 . Body mass index ( BMI ) great equal 18.00 kg/m2 30.00 kg/m2 7 . Non exsmoker ; 8 . Endometrium thickness â‰¤4 mm ultrasonography screen 9 . Negative mammogram ( date &lt; 2 year ) 10 . Negative Pap smear test ( date &lt; 1 year ) 11 . Normal clinical breast examination 12 . Normal pelvic examination 13 . Have clinically significant disease capture medical history evidence clinically significant finding physical examination , determine medical investigator 14 . Willingness adhere protocol requirement evidence informed consent form ( ICF ) duly read , sign date subject 1 . Use estrogen , progestin , estrogen/progestin drug product , androgen , selective estrogen receptor modulators ( SERMs ) , phytoestrogen supplement natural product ( soy , black cohosh , dong quai ) past 3 month screen visit 2 . Use estrogen , progestin androgen pellet injectable therapy past 6 month screen visit 3 . Contraindications hormone therapy : Active liver dysfunction disease history severe liver disease Known , suspect past history hepatic tumor ( benign malign ) Active past history arterial thromboembolic disease ( e.g . angina , myocardial infarction , stroke , coronary heart disease , transient ischemic attack ) Active past history venous thromboembolism ( e.g . deep venous thrombosis , pulmonary embolism ) active thrombophlebitis Known , suspect past history breast cancer Known , suspect past history estrogendependent progestindependent malignant neoplasia ( e.g . endometrial cancer ) Endometrial hyperplasia Porphyria cutanea tarda Genital bleeding Untreated hypertension Classical migraine Partial complete loss vision diplopia due ophthalmic vascular disease 4 . Presence clinically significant screen ECG abnormality define medical judgment 5 . Presence polyps 6 . Presence uterine fibroid abnormality affect endometrial thickness measurement preclude estrogen therapy 7 . Known hypersensitivity active substance excipients contain drug product particular soya peanut , well hereditary problem fructose intolerance phenylketonuria 8 . Participation concurrent clinical trial another trial within past 2 month 9 . Use enzymemodifying drug , include strong inhibitor cytochrome P450 ( CYP ) enzymes ( cimetidine , fluoxetine , quinidine , erythromycin , ciprofloxacin , fluconazole , ketoconazole , diltiazem HIV antiviral ) strong inducer CYP enzyme ( barbiturate , carbamazepine , glucocorticoid , phenytoin , rifampin St John 's Wort ) , previous 28 day day 1 study 10 . Maintenance therapy drug significant history drug dependency , drug abuse alcohol abuse within last 2 year 11 . Presence medical condition circumstance would significantly decrease chance obtain reliable data , achieve study objective complete study 12 . Serious psychiatric problem ( whether receive treatment ) case compromise patient 's reliability 13 . Any clinically significant illness previous 28 day day 1 study 14 . Any history tuberculosis and/or prophylaxis tuberculosis 15 . Positive screen alcohol and/or drug abuse 16 . Positive result HIV Ag/Ab combo , hepatitis B surface antigen hepatitis C virus test 17 . Females pregnant accord positive serum pregnancy test 18 . Presumption subject 's poor reliability/cooperation 19 . Any reason , opinion Investigator , would prevent subject participate study</criteria>
	<gender>Female</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>